ERG, EVI1 and PRAME Are Relevant Markers of Treatment Response and Survival, and They Could Be Useful for Improving the Risk-Stratification in Citogenetically Normal Acute Myeloid Leukemia (CN-AML)

MLA

Santamaría, Carlos, et al. “ERG, EVI1 and PRAME Are Relevant Markers of Treatment Response and Survival, and They Could Be Useful for Improving the Risk-Stratification in Citogenetically Normal Acute Myeloid Leukemia (CN-AML).” Blood, vol. 112, no. 11, Nov. 2008, p. 4844. EBSCOhost, https://doi.org/10.1182/blood.V112.11.4844.4844.

APA

Santamaría, C., Chillón, C., García-Sanz, R., Pérez, C., Ramos, F., de Coca, A. G., Alonso, J.-M., Giraldo, P., Bernal, T., Queizán, J.-A., Rodríguez, J. N., Fernández-Abellán, P., Barez, A., Peñarrubia, M.-J., Amigo, M. L., García-Sancho, A. M., Pozas, M. A., Balanzategui, A., Díaz-Mediavilla, J., … González, M. (2008). ERG, EVI1 and PRAME Are Relevant Markers of Treatment Response and Survival, and They Could Be Useful for Improving the Risk-Stratification in Citogenetically Normal Acute Myeloid Leukemia (CN-AML). Blood, 112(11), 4844. https://doi.org/10.1182/blood.V112.11.4844.4844

Chicago

Santamaría, Carlos, Carmen Chillón, Ramon García-Sanz, Cristina Pérez, Fernando Ramos, Alfonso García de Coca, Jose- Maria Alonso, et al. 2008. “ERG, EVI1 and PRAME Are Relevant Markers of Treatment Response and Survival, and They Could Be Useful for Improving the Risk-Stratification in Citogenetically Normal Acute Myeloid Leukemia (CN-AML).” Blood 112 (11): 4844. doi:10.1182/blood.V112.11.4844.4844.